Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
Clinical Trials01:16

Clinical Trials

11.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

333
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
333
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

516
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
516
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.7K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Wurtzite InP/ZnSe/ZnS Core/Shell Semiconductor Quantum Dots with Bright Near-IR Emission.

Journal of the American Chemical Society·2026
Same author

irAE.AI: AI-powered exploration of real-world immune-related adverse events.

JAMIA open·2026
Same author

Open surgery appears to be the preferred treatment in patients with nutcracker syndrome: A vascular low frequency disease consortium analysis.

Journal of vascular surgery. Venous and lymphatic disorders·2026
Same author

Comprehensive Mapping of Immune Nanobody Repertoires with NanoMAP.

bioRxiv : the preprint server for biology·2026
Same author

A problem of Epic proportion.

PLOS digital health·2026
Same author

Improving sepsis care with Artificial Intelligence. What would Illich say?

Critical care science·2026

Related Experiment Video

Updated: Mar 30, 2026

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

3.2K

From Pharmacovigilance to Clinical Care Optimization.

Leo Anthony Celi1, Edward Moseley2, Christopher Moses3

  • 1Institute for Medical Engineering and Science, Massachusetts Institute of Technology , Cambridge, Massachusetts.

Big Data
|November 18, 2015
PubMed
Summary

Improved drug safety surveillance is needed for new pharmaceuticals. A proposed open, de-identified database will enhance pharmacovigilance by analyzing real-world patient data to detect adverse events and drug effects.

More Related Videos

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.4K
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.8K

Related Experiment Videos

Last Updated: Mar 30, 2026

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

3.2K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.4K
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.8K

Area of Science:

  • Pharmacovigilance and Pharmacoepidemiology
  • Health Informatics
  • Data Science in Medicine

Background:

  • Current post-market drug surveillance has limitations in capturing diverse patient populations and rare adverse events.
  • Randomized controlled trials often exclude individuals with specific characteristics, limiting real-world safety data.
  • Digitized healthcare data offers a rich resource for improved pharmaceutical safety monitoring.

Purpose of the Study:

  • To propose the development of an open, accessible database for enhanced pharmacovigilance.
  • To create a platform for identifying delayed and low-frequency adverse drug events.
  • To leverage real-world data for detecting drug interactions and subpopulation effects.

Main Methods:

  • Development of an open, de-identified data repository.
  • Utilizing digitized medical data for observational studies.
  • Applying advanced analytic techniques to identify safety signals.

Main Results:

  • The proposed database can identify delayed and low-frequency adverse events.
  • It can detect complex drug interactions and novel therapeutic uses.
  • Demonstrated potential through experience with the MIMIC database.

Conclusions:

  • An open, digitized pharmacovigilance database can significantly improve drug safety monitoring.
  • This approach can inform clinical practice guidelines and optimize healthcare resource allocation.
  • Standardized, digitized pharmacovigilance is essential for safe and efficient pharmaceutical administration.